Immunosuppression minimization: current and future trends in transplant immunosuppression
F Vincenti - Journal of the American Society of Nephrology, 2003 - journals.lww.com
The past decade has witnessed unprecedented advances in renal transplantation propelled
by novel and effective immunosuppression drugs. The introduction of mycophenolate mofetil
(MMF), tacrolimus, cyclosporine microemulsion, sirolimus, a new generation of monoclonal
antibodies (the anti–interleukin-2 receptor blockers, daclizumab and basiliximab), and the
depleting polyclonal biologic Thymoglobulin has provided transplant physicians with a wide
choice in selecting effective immunosuppression regimens (1–5). The intensification of …
by novel and effective immunosuppression drugs. The introduction of mycophenolate mofetil
(MMF), tacrolimus, cyclosporine microemulsion, sirolimus, a new generation of monoclonal
antibodies (the anti–interleukin-2 receptor blockers, daclizumab and basiliximab), and the
depleting polyclonal biologic Thymoglobulin has provided transplant physicians with a wide
choice in selecting effective immunosuppression regimens (1–5). The intensification of …